Making Drug Effects Visible in the Healthy Brain: TMS-EEG in Phase 1 Epilepsy Trials
In Phase 1 epilepsy drug trials involving healthy volunteers, there are no seizures to monitor. Researchers therefore face a different question: does the drug produce a measurable brain response consistent with its intended action?
Combining transcranial magnetic stimulation with electroencephalography (TMS-EEG), offers a way to investigate this question, linking early safety and drug-exposure data with evidence of changes in brain activity.
Phase 1: Measuring Drug Activity in Healthy Volunteers
In Phase 1 studies involving small cohorts of healthy volunteers, researchers assess safety and tolerability, investigate how the body handles the drug, and seek early evidence of its intended biological effects. These studies do not aim to demonstrate seizure reduction or effects on seizure activity. Instead, their findings help researchers move towards Phase 2 testing in people with epilepsy.
For a drug designed to act in the brain, measuring biological effects in healthy volunteers can make this early stage more informative.
Three complementary assessments help characterise a drug in healthy volunteers:
- Safety and tolerability assessments monitor effects such as dizziness, sleepiness, and changes in thinking and memory.
- Pharmacokinetics describe how the drug is absorbed, distributed, broken down and cleared, and is central to drug studies, particularly Phase 1.
- Pharmacodynamics examine what the drug does to the body; for a brain-acting drug, this includes asking whether the measured brain response is consistent with its intended action.
Together, these assessments and markers help researchers select the doses to carry forward, considering tolerability alongside evidence of biological activity. A measurable brain response can help connect the dose given to what the drug does.
For epilepsy drugs, this creates a measurement challenge. The healthy volunteers don't have seizures, so seizure reduction cannot provide the readout.
Researchers need an alternative measure of drug-related changes in brain function. The purpose is not to reproduce or cause epilepsy in healthy volunteers, but to obtain evidence of pharmacological activity that can strengthen Phase 1 dose-selection and development decisions.
EEG and TMS: Making Effects Measurable Without Seizures
A starting point is electroencephalography (EEG). Small electrodes on the scalp record the brain's electrical activity. In healthy-volunteer Phase 1 studies, its relevance is the opportunity to measure changes in brain activity following drug administration, rather than to identify seizures.
Because EEG records activity millisecond by millisecond and is safe and repeatable, researchers can compare recordings from healthy volunteers before and after dosing. These comparisons provide a way to investigate drug effects even when there is no seizure activity to measure. Drug-related changes in EEG can provide evidence that a drug affects brain activity in healthy volunteers.
Different drug types can alter brain rhythms in different ways; for example, drugs that block sodium channels can slow the background rhythm. These changes can inform Phase 1 and later development, but do not by themselves establish engagement of a specific molecular target.
EEG also has measurement limits: it mainly records spontaneous brain activity and captures deep structures poorly. With no abnormal seizure activity to track in healthy volunteers, spontaneous recordings may provide only a limited measure of the drug effect of interest. A complementary approach is therefore needed to investigate intended effects through a controlled brain response.
Transcranial magnetic stimulation (TMS), offers a complementary approach. Instead of relying only on spontaneous activity, researchers deliver a controlled stimulus and measure the response.
In healthy volunteers, this creates an opportunity to investigate how a drug changes brain responsiveness without using seizures as the measure. A coil held against the scalp sends out a brief magnetic pulse, creating a tiny electrical current in the cortex underneath. When the pulse is applied over the motor cortex, it produces a small muscle twitch that sensors on the skin can measure. By changing the pulse pattern, researchers can explore different aspects of brain function.
Each measure tells a different part of the story.
- Motor threshold reflects how easily brain cells are excited; sodium channel blockers, a common type of antiseizure drug, raise it.
- Short-interval inhibition reflects the brain's main "brake", involving the chemical messenger GABA acting on GABA-A receptors. Drugs such as benzodiazepines strengthen this response.
- Long-interval inhibition captures a slower braking system involving GABA-B receptors, helping researchers tell the two apart. Facilitation relates to glutamate, the brain's main "accelerator", and is reduced by some antiseizure drugs.
For healthy-volunteer Phase 1 studies, these measures offer ways to test whether a drug changes excitation or inhibition in a manner consistent with its proposed mechanism.
TMS is non-invasive, painless for most people and repeatable, and can detect drug effects in small groups. Its value here is as a measure of pharmacological activity, not as a test of seizure reduction.
The drawback is that measuring a muscle twitch limits this approach to the motor cortex, leaving much of the brain out of reach. Results can also vary from person to person and between sessions, so consistent methods are important. TMS carries a small seizure risk, which makes screening, safety limits and trained operators essential.
TMS-EEG: Connecting Drug Exposure with Brain Response in Phase 1
Combining TMS with EEG brings the focus back to measuring drug effects in the healthy brain. TMS supplies a controlled stimulus, while EEG records the response across the scalp, millisecond by millisecond. Researchers need neither spontaneous seizure activity nor a muscle twitch as their readout, allowing them to investigate cortical responses beyond the motor cortex.
After each pulse, the recording shows a sequence of peaks called TMS-evoked potentials. The early peaks relate to how excitable the cortex is. One at around 45 milliseconds, known as N45, is thought to reflect GABA-A activity; another at around 100 milliseconds, N100, is thought to reflect GABA-B activity. The pulse also changes brain rhythms, including beta and gamma waves, giving researchers another way to explore how brain networks behave.
In healthy volunteers, these responses offer a way to explore whether an investigational drug produces changes consistent with its intended mechanism. Measures sensitive to sodium channel, potassium channel, GABA-A and GABA-B effects may help researchers characterise its pharmacological activity.
The Phase 1 question remains specific: can a drug-related change in cortical responsiveness be detected when there are no seizures to count?
The practical value in Phase 1 is to connect dose and drug exposure with a measurable brain response in healthy volunteers. TMS-EEG can investigate changes in excitability and inhibition, how those changes vary with dose, and how they relate to drug concentrations in the blood. A well-understood reference drug can help check that the method detects an expected effect.
Together, these findings can support evidence consistent with target engagement and inform dose selection, without constituting proof of antiseizure efficacy.
What a Healthy-Volunteer Brain Response Can and Cannot Show
Making a drug effect measurable is only useful if the signal can be interpreted reliably.
TMS-EEG is technically demanding: the coil's click and the sensation of the pulse on the scalp can contribute to the recorded response. It cannot directly reach deep structures such as the hippocampus, and its measures provide clues about receptor and channel activity rather than direct readings.
Methods are still being standardised, and regulatory acceptance is developing, so findings do not always transfer easily between studies or settings. In healthy volunteers, an observed response should therefore be interpreted as evidence of pharmacodynamic activity, not definitive proof of a specific mechanism or therapeutic benefit.
This distinction matters for epilepsy drugs designed to act on specific mechanisms, including particular ion channel subtypes such as Kv7 and Nav1.6.
In healthy-volunteer Phase 1 studies, the immediate aim is to ask whether exposure to such a drug is accompanied by the expected pattern of brain response. Keeping that question central helps separate evidence of biological activity from claims about treatment effectiveness.
TMS-EEG could strengthen healthy-volunteer Phase 1 studies by adding measures of brain response to safety, tolerability and pharmacokinetic data. It is not yet routine.
Wider use depends on validation, consistent methods and reference compounds against which new drug effects can be compared. The goal is a dependable way to investigate whether a drug is acting in the brain as intended and which doses produce measurable effects.
When there are no seizures to count, Phase 1 still needs ways to measure what an epilepsy drug does in the healthy brain. TMS-EEG offers one approach: pairing a controlled stimulus with EEG recordings of cortical responses to investigate drug-related changes in excitability and inhibition. Its promise is not to demonstrate seizure control in healthy volunteers, but to bridge the gap between knowing that a drug can be administered and finding evidence that it produces the intended brain effects.
With appropriate validation and interpretation, that evidence can make Phase 1 dose-selection and development decisions better informed.
Specialist Support for Healthy-Volunteer Phase 1 Trials
At The Science Behind, we work closely with our MHRA-accredited Phase 1 CRO partners and our Sponsor clients to bring together the expertise and equipment these studies need. We specialise in helping teams design, enhance and put these techniques into practice in Phase 1 clinical trials.
For healthy-volunteer studies, the focus is the question running throughout this article: how can we make a drug's effects in the brain measurable alongside safety, tolerability and exposure?
References
1. U.S. Food and Drug Administration. Step 3: Clinical Research. Accessed 26 October 2026.
2. Ziemann U, Reis J, Schwenkreis P, et al. TMS and drugs revisited 2014. Clinical Neurophysiology.2015;126(10):1847–1868. doi:10.1016/j.clinph.2014.08.028.
3. Premoli I, Castellanos N, Rivolta D, et al. TMS-EEG signatures of GABAergic neurotransmission in the human cortex. Journal of Neuroscience. 2014;34(16):5603–5612. doi:10.1523/JNEUROSCI.5089-13.2014.
4. Darmani G, Bergmann TO, Zipser C, Baur D, Müller-Dahlhaus F, Ziemann U. Effects of antiepileptic drugs on cortical excitability in humans: A TMS-EMG and TMS-EEG study. Human Brain Mapping. 2019;40(4):1276–1289. doi:10.1002/hbm.24448.
5. Darmani G, Ziemann U. Pharmacophysiology of TMS-evoked EEG potentials: A mini-review. Brain Stimulation.2019;12(3):829–831. doi:10.1016/j.brs.2019.02.021.
6. Tsuboyama M, Kaye HL, Rotenberg A. Biomarkers obtained by transcranial magnetic stimulation of the motor cortex in epilepsy. Frontiers in Integrative Neuroscience. 2019;13:57. doi:10.3389/fnint.2019.00057.
7. Rogasch NC, Sullivan C, Thomson RH, et al. Analysing concurrent transcranial magnetic stimulation and electroencephalographic data: A review and introduction to the open-source TESA software. NeuroImage.2017;147:934–951. doi:10.1016/j.neuroimage.2016.10.031.

